OBJECTIVES: To further understand the mechanism of intermediate-level glycopeptide resistance, resulting from multiple endogenous mutations, in both laboratory-derived and clinically isolated Staphylococcus aureus. METHODS: Laboratory-derived S. aureus strains were generated under selection using a variety of cell-wall-active antibiotics. Complete sequences of 27 genes, including 17 two-component histidine kinase sensors, were then compared with those of their susceptible parent strain. Further genetic analysis was performed on 125 clinical S. aureus isolates and 42 geographically diverse isolates of vancomycin-intermediate S. aureus (VISA). RESULTS: Selective pressure using imipenem resulted in single point mutations leading to amino acid substitutions in two genes: vraS, encoding a two-component histidine kinase sensor; and SA1702 (also called yvqF, located immediately upstream of vraS), encoding a conserved hypothetical protein. The accumulation of the mutation in two distinct proteins-MsrR, a peptide methionine sulphoxide reductase regulator, and TcaA, a teicoplanin-resistance-associated protein-correlated with further increases in the glycopeptide MIC. The prevalence of YvqF/VraSR mutants among 125 clinical isolates along with the corresponding teicoplanin MICs was as follows: 0% (0/39), < or =1 mg/L; 48.6% (17/35), 2 mg/L; 72.7% (24/33), 4 mg/L; 93.8% (15/16), 8 mg/L; and 100% (2/2), 16 mg/L. Genetic analysis of 42 VISA isolates also identified the predominant amino acid substitutions in YvqF/VraS: 9 isolates (21.4%) revealed mutations in YvqF, followed by 7 isolates with mutations in VraS (16.7%). CONCLUSIONS: Our findings provide novel insights into the high prevalence and genetic diversity of YvqF/VraSR mutants among clinical S. aureus isolates with reduced susceptibility to teicoplanin.
OBJECTIVES: To further understand the mechanism of intermediate-level glycopeptide resistance, resulting from multiple endogenous mutations, in both laboratory-derived and clinically isolated Staphylococcus aureus. METHODS: Laboratory-derived S. aureus strains were generated under selection using a variety of cell-wall-active antibiotics. Complete sequences of 27 genes, including 17 two-component histidine kinase sensors, were then compared with those of their susceptible parent strain. Further genetic analysis was performed on 125 clinical S. aureus isolates and 42 geographically diverse isolates of vancomycin-intermediate S. aureus (VISA). RESULTS: Selective pressure using imipenem resulted in single point mutations leading to amino acid substitutions in two genes: vraS, encoding a two-component histidine kinase sensor; and SA1702 (also called yvqF, located immediately upstream of vraS), encoding a conserved hypothetical protein. The accumulation of the mutation in two distinct proteins-MsrR, a peptide methionine sulphoxide reductase regulator, and TcaA, a teicoplanin-resistance-associated protein-correlated with further increases in the glycopeptide MIC. The prevalence of YvqF/VraSR mutants among 125 clinical isolates along with the corresponding teicoplanin MICs was as follows: 0% (0/39), < or =1 mg/L; 48.6% (17/35), 2 mg/L; 72.7% (24/33), 4 mg/L; 93.8% (15/16), 8 mg/L; and 100% (2/2), 16 mg/L. Genetic analysis of 42 VISA isolates also identified the predominant amino acid substitutions in YvqF/VraS: 9 isolates (21.4%) revealed mutations in YvqF, followed by 7 isolates with mutations in VraS (16.7%). CONCLUSIONS: Our findings provide novel insights into the high prevalence and genetic diversity of YvqF/VraSR mutants among clinical S. aureus isolates with reduced susceptibility to teicoplanin.
Authors: N Kondo; K Kuwahara-Arai; H Kuroda-Murakami; E Tateda-Suzuki; K Hiramatsu Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191
Authors: M Kuroda; T Ohta; I Uchiyama; T Baba; H Yuzawa; I Kobayashi; L Cui; A Oguchi; K Aoki; Y Nagai; J Lian; T Ito; M Kanamori; H Matsumaru; A Maruyama; H Murakami; A Hosoyama; Y Mizutani-Ui; N K Takahashi; T Sawano; R Inoue; C Kaito; K Sekimizu; H Hirakawa; S Kuhara; S Goto; J Yabuzaki; M Kanehisa; A Yamashita; K Oshima; K Furuya; C Yoshino; T Shiba; M Hattori; N Ogasawara; H Hayashi; K Hiramatsu Journal: Lancet Date: 2001-04-21 Impact factor: 79.321
Authors: George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191
Authors: Adriana Renzoni; William L Kelley; Christine Barras; Antoinette Monod; Elzbieta Huggler; Patrice François; Jacques Schrenzel; René Studer; Pierre Vaudaux; Daniel P Lew Journal: Antimicrob Agents Chemother Date: 2008-12-22 Impact factor: 5.191
Authors: Benjamin P Howden; Danielle J Smith; Ashley Mansell; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies Journal: BMC Microbiol Date: 2008-02-27 Impact factor: 3.605
Authors: Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace Journal: Cold Spring Harb Perspect Med Date: 2016-12-01 Impact factor: 6.915
Authors: Elena Galbusera; Adriana Renzoni; Diego O Andrey; Antoinette Monod; Christine Barras; Paolo Tortora; Alessandra Polissi; William L Kelley Journal: Antimicrob Agents Chemother Date: 2010-12-20 Impact factor: 5.191
Authors: Calvin Ho-Fung Lau; Sebastien Fraud; Marcus Jones; Scott N Peterson; Keith Poole Journal: Antimicrob Agents Chemother Date: 2013-03-04 Impact factor: 5.191